80259-18-3 Usage
Uses
Used in Pharmaceutical Industry:
N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine is used as a therapeutic agent for the treatment or prevention of nephropathy. Its α2-adrenoceptor blocking properties help in managing the symptoms and progression of kidney diseases by modulating the activity of the adrenergic system.
Used in Research Applications:
In addition to its clinical use, N-(4-(4-Methyl-1-piperazinyl)phenyl)-9-acridinamine can also be employed as a research tool in the study of α2-adrenergic receptors and their role in various physiological and pathological processes. This can contribute to the development of new drugs and therapies targeting these receptors for different medical conditions.
Biological Activity
α 2C -adrenoceptor antagonist that displays ~ 50-fold selectivity over other α 2 -adrenoceptor subtypes (K i values are 28, 1470, 1700 and 3150 nM for human α 2C , α 2B , α 2D and α 2A subtypes respectively). Potently antagonizes adrenalin-stimulated 35 GTP γ S binding in vitro (K B = 16 nM) and produces antidepressant and antipsychotic-like effects in vivo .
Check Digit Verification of cas no
The CAS Registry Mumber 80259-18-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,0,2,5 and 9 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 80259-18:
(7*8)+(6*0)+(5*2)+(4*5)+(3*9)+(2*1)+(1*8)=123
123 % 10 = 3
So 80259-18-3 is a valid CAS Registry Number.
InChI:InChI=1/C24H24N4/c1-27-14-16-28(17-15-27)19-12-10-18(11-13-19)25-24-20-6-2-4-8-22(20)26-23-9-5-3-7-21(23)24/h2-13H,14-17H2,1H3,(H,25,26)
80259-18-3Relevant academic research and scientific papers
Derivatives of quinoline as alpha-2 antagonists
-
, (2008/06/13)
A compound of formula I, wherein A, Ra, Rb, R1 to R5, m and t are as defined as disclosed, or a pharmaceutically acceptable salt or ester thereof, useful as an alpha-2 antagonist. The compounds I can be used for the treatment of diseases or conditions where alpha-2 antagonists are indicated to be effective.
